Idiotype Immunization Following High-Dose Therapy and Autologous Stem Cell Transplantation for Non-Hodgkin Lymphoma

Peter R Holman; Caitlin Costello; Margarida deMagalhaes-Silverman; Sue Corringham; Januario Castro; Edward D Ball

doi:10.1016/j.bbmt.2011.06.011

Back

Idiotype Immunization Following High-Dose Therapy and Autologous Stem Cell Transplantation for Non-Hodgkin Lymphoma

Journal article

Open access

Peer reviewed

Idiotype Immunization Following High-Dose Therapy and Autologous Stem Cell Transplantation for Non-Hodgkin Lymphoma

Peter R Holman, Caitlin Costello, Margarida deMagalhaes-Silverman, Sue Corringham, Januario Castro and Edward D Ball

Biology of blood and marrow transplantation, Vol.18(2), pp.257-264

2012

DOI: 10.1016/j.bbmt.2011.06.011

PMID: 21736867

Files and links (1)

url

https://doi.org/10.1016/j.bbmt.2011.06.011View

Published (Version of record) Open Access

Abstract

The treatment of low- and intermediate-grade subtypes of malignant lymphoma continues to evolve. Mantle cell lymphoma (MCL) accounts for 6% of all non-Hodgkin lymphoma (NHL) and is generally considered incurable. Although high response rates can be achieved with initial chemotherapy, median survival is only 3-4 years. Intensified consolidation with high-dose therapy (HDT) and autologous stem cell transplantation (ASCT) has been reported to improve progression-free survival (PFS), but most patients eventually relapse. Indolent lymphoma accounts for 35% of all NHL and is associated with a median survival of 9 years. Similar to MCL, it is also generally considered incurable, and the PFS also appears to be improved following HDT/ASCT. We initiated a pilot study to evaluate idiotype (Id) vaccination following HDT and ASCT for patients with MCL, indolent, and transformed NHL to evaluate the ability of Id-keyhole limpet hemocyanin (KLH) to induce immune responses, and to evaluate overall survival (OS) and PFS. We treated 15 patients: 8 with MCL, 4 with follicular lymphoma, 1 with small lymphocytic lymphoma, and 2 with transformed lymphoma. After a median follow-up of approximately 6.3 years (range: 1-9), PFS and OS at 9.05 years from time of ASCT are 59% and 52%, respectively.

Non-Hodgkin lymphoma

Immunotherapy

Autologous stem cell transplantation

Idiotype vaccination

Details

Title: Subtitle: Idiotype Immunization Following High-Dose Therapy and Autologous Stem Cell Transplantation for Non-Hodgkin Lymphoma
Creators: Peter R Holman - Moores UCSD Cancer Center, Blood and Marrow Transplantation Division, La Jolla, California
Caitlin Costello - Moores UCSD Cancer Center, Blood and Marrow Transplantation Division, La Jolla, California
Margarida deMagalhaes-Silverman - University of Iowa, Iowa City, Iowa
Sue Corringham - Moores UCSD Cancer Center, Blood and Marrow Transplantation Division, La Jolla, California
Januario Castro - Moores UCSD Cancer Center, Blood and Marrow Transplantation Division, La Jolla, California
Edward D Ball - Moores UCSD Cancer Center, Blood and Marrow Transplantation Division, La Jolla, California
Resource Type: Journal article
Publication Details: Biology of blood and marrow transplantation, Vol.18(2), pp.257-264
DOI: 10.1016/j.bbmt.2011.06.011
PMID: 21736867
NLM abbreviation: Biol Blood Marrow Transplant
ISSN: 1083-8791
eISSN: 1523-6536
Publisher: Elsevier Inc
Language: English
Date published: 2012
Academic Unit: Hematology, Oncology, and Blood & Marrow Transplantation; Internal Medicine
Record Identifier: 9984094367602771

Metrics

10 Record Views

7 Times Cited - Web of Science